过去 90 天内没有内部人买入。最近一笔由 Bengal Impact Partners, LLC 披露于 2023年5月17日。
Body & Mind Inc.:高管交易动态
Body & Mind Inc.是一家医疗与制药行业的上市公司。其高管通过SEC (Form 4)申报股份交易。过去十二个月内,Body & Mind Inc.没有任何高管发布申报。最近一份申报的日期是2024年2月14日。
我们关于Body & Mind Inc.的记录可追溯至2018年,累计有10笔买入和72笔卖出。
数据来源:高管申报(SEC (Form 4))。过往交易不代表未来收益。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位;其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2023财年截至 2023年7月 · cache
- 2,700,393 股@ US$0.066786.0% 占其流量股票SEC:0001104659-24-023153:0
- 671,642 股@ US$0.044514.0% 占其流量股票SEC:0001104659-23-062011:0标准退出:2023年8月6日 (T+90)
- 20,000 股@ US$0.1521.4% 占其流量股票SEC:0001183740-22-000105:0标准退出:2022年8月2日 (T+90)
- 109,000 股@ US$0.2477.7% 占其流量股票SEC:0001183740-22-000071:0标准退出:2022年6月20日 (T+90)
- 25,000 股@ US$0.2541.8% 占其流量股票SEC:0001183740-22-000028:0标准退出:2022年5月4日 (T+90)
- 16,667 股@ US$0.36100.0% 占其流量股票SEC:0001183740-22-000010:0标准退出:2022年4月11日 (T+90)
- 20,000 股@ US$0.38522.3% 占其流量股票SEC:0001183740-21-000322:0标准退出:2022年3月23日 (T+90)
- 20,000 股@ US$0.27536.8% 占其流量股票SEC:0001183740-21-000321:0标准退出:2022年3月22日 (T+90)
- 5,900,000 股@ US$0.237148.5% 占其流量股票SEC:0001183740-21-000236:0
- 4,000,000 股@ US$0.236533.2% 占其流量股票SEC:0001183740-21-000225:0
- 6,500 股@ US$0.35470.1% 占其流量股票SEC:0001183740-21-000220:0
- 20,500 股@ US$0.36550.3% 占其流量股票SEC:0001183740-21-000215:0
- 15,000 股@ US$0.35350.2% 占其流量股票SEC:0001183740-21-000214:0
- 17,000 股@ US$0.35690.2% 占其流量股票SEC:0001183740-21-000216:0
- 8,000 股@ US$0.35540.1% 占其流量股票SEC:0001183740-21-000219:0
- 18,000 股@ US$0.36070.2% 占其流量股票SEC:0001183740-21-000217:0
- 3,500 股@ US$0.34120.0% 占其流量股票SEC:0001183740-21-000213:0
- 15,500 股@ US$0.35730.2% 占其流量股票SEC:0001183740-21-000218:0
- 5,500 股@ US$0.32780.1% 占其流量股票SEC:0001183740-21-000209:0
- 13,000 股@ US$0.33780.2% 占其流量股票SEC:0001183740-21-000207:0
- 500 股@ US$0.36050.0% 占其流量股票SEC:0001183740-21-000206:0
- 2,500 股@ US$0.34970.0% 占其流量股票SEC:0001183740-21-000205:0
- 14,000 股@ US$0.33470.2% 占其流量股票SEC:0001183740-21-000208:0
- 21,000 股@ US$0.34220.2% 占其流量股票SEC:0001183740-21-000192:0
- 38,000 股@ US$0.3290.4% 占其流量股票SEC:0001183740-21-000191:0
87 条申报中的 25 条
About Body & Mind Inc.
Body and Mind Inc. (ticker BAMM) is a United States cannabis operator with investor communications aimed at North American capital markets. For the purpose of this brief, it should be viewed as a health-and-wellness adjacent equity within the broader U.S. listed universe, with investor attention often centered on insider activity disclosures and corporate events relevant to the NASDAQ/NYSE ecosystem. The company was originally formed as Deploy Technologies, then renamed Body and Mind Inc. after it completed the acquisition of Nevada Medical Group in November 2017. Since then, it has pursued a multi-state cannabis model combining cultivation, processing, and retail. Its operational footprint is associated with Las Vegas, Nevada, while its corporate history also includes Vancouver, underscoring its cross-border origins.\n\nBody and Mind builds and markets cannabis products under its BaM brand and, depending on local licenses and market conditions, operates dispensaries and production assets across selected U.S. states. Its product mix includes flower, pre-rolls, concentrates, vape cartridges, and edibles, with an emphasis on craft-oriented production, state-compliant testing, and brand consistency. The company is best described as a niche operator rather than a national scale leader. Its competitive position stems from operational know-how in limited-license jurisdictions, selective brand building, and a geographically diversified footprint rather than from sheer volume or market share dominance.\n\nGeographically, Body and Mind has historically maintained operations or projects in California, Nevada, Ohio, Arkansas, Michigan, as well as assets or initiatives linked to Illinois and New Jersey. This footprint reflects a state-by-state strategy aimed at capturing growth in regulated cannabis markets with different consumer profiles and licensing regimes. Recent developments have included continued portfolio optimization and asset transactions in 2025, including moves tied to dispensary and state-level operations. For French-speaking investors, BAMM is therefore a special-situations micro-cap cannabis name: attractive for its operating optionality, but also exposed to regulatory risk, local licensing constraints, balance-sheet sensitivity, and the liquidity profile typical of smaller U.S. listed names.